Advench Pharmaceutical Private Limited

Feature -

• Generic Name: Tenecteplase
• Strength & Pack: 40 mg injection (lyophilized powder with sterile water for reconstitution).
• Therapeutic Class: Thrombolytic / Fibrinolytic agent.
• Indication:
• Used for acute ST-elevation myocardial infarction (STEMI).
• Helps dissolve blood clots, restore blood flow, and reduce heart muscle damage.
• Mechanism of Action: Genetically engineered variant of tissue plasminogen activator (tPA) that binds to fibrin in clots and activates plasminogen to plasmin, leading to clot breakdown.
• Route of Administration: Intravenous (IV bolus injection).

Feature -

• Brand Name: Alburel
• Active Ingredient: Human Albumin (plasma protein fraction)
• Strength & Pack: Available in 5% and 20% solutions in vials (commonly 50 ml, 100 ml, 250 ml, 500 ml packs depending on strength).
• Therapeutic Class: Plasma volume expander / Blood product derivative
• Indication:
• Treatment of hypovolemia (blood volume loss due to shock, burns, trauma, surgery).
• Management of hypoalbuminemia in liver cirrhosis, nephrotic syndrome, or critical illness.
• Used in plasma exchange, cardiopulmonary bypass, and acute liver failure.

Feature -

• Generic Name: Tenecteplase
• Strength & Pack: 30 mg injection (lyophilized powder for reconstitution with sterile water).
• Therapeutic Class: Thrombolytic agent (fibrinolytic).
• Indication:
• Used in the management of acute myocardial infarction (STEMI) for dissolving blood clots.
• Helps in restoring coronary artery blood flow and reducing mortality.
• Mechanism of Action: Recombinant tissue plasminogen activator (tPA) variant that binds fibrin and converts plasminogen to plasmin, breaking down fibrin clots.
• Route of Administration: Intravenous (IV) bolus injection.

Renocrit Injection contains Recombinant Human Erythropoietin Alfa, a biologically active protein used to stimulate the production of red blood cells in patients suffering from anemia. This injectable medicine is primarily prescribed to treat anemia associated with chronic kidney disease (CKD), chemotherapy, HIV treatment, and other medical conditions where red blood cell production is insufficient. Renocrit promotes erythropoiesis by mimicking the natural hormone erythropoietin, thereby improving oxygen delivery to tissues and reducing symptoms like fatigue, weakness, and shortness of breath related to anemia. This injection is manufactured under strict quality control standards to ensure safety and efficacy. It is intended for use under medical supervision, with dosing tailored based on individual patient needs and response. Common side effects may include mild fever, headache, nausea, hypertension, and injection site reactions. Use with caution in patients with cardiovascular issues or hypertension. Renocrit Injection should be stored refrigerated between 2°C to 8°C and protected from freezing and light to maintain its stability and potency. The product complies with pharmaceutical quality standards, ensuring consistent therapeutic benefits.